TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

Company Performance - TG Therapeutics reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share, compared to a loss of $0.07 per share a year ago, representing an earnings surprise of -83.33% [1] - The company posted revenues of $120.86 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.99%, and showing a significant increase from year-ago revenues of $63.47 million [2] - Over the last four quarters, TG Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - TG Therapeutics shares have increased approximately 44.3% since the beginning of the year, while the S&P 500 has declined by -3.3% [3] - The current consensus EPS estimate for the coming quarter is $0.22 on revenues of $131.03 million, and for the current fiscal year, it is $0.98 on revenues of $545.6 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TG Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]